Furthermore, USP27x is present in complex with BCL2L11 and BTRC, which facilitates BCL2L11 degradation in response to mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling and sensitizes human cancer cells to chemotherapeutic drugs [36]. The gene discussed is BCL2L11; the disease is cancer.